Compare Cassava Sciences Inc (FLNA) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs General Motors Company — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while General Motors Company trades at $77.41 (market cap $70.01B). The key difference: General Motors Company is far larger — about 1317.5× Cassava Sciences Inc's market cap, and General Motors Company pays a 0.93% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | GM | |
|---|---|---|
Market Cap | $53.14M | $70.01B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $86.38 |
52-Week Low | $1.09 | $48.89 |
Enterprise Value | -$33.43M | $173.34B |
Dividend Yield | — | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
General Motors (GM) trades at $76.78, down 0.12% on the day, with a neutral technical signal and strong analyst support (63% buy ratings). Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $3.70 surpassing the $2.61 estimate. Revenue for 2025 was $185.02B, though net income margin narrowed to 1.38%. The company maintains solid cash flow from operations of $26.87B in 2025 and recently announced a $0.18 dividend for H1 2026.
GM presents a value opportunity with low P/S (0.4) and P/B (1.12) ratios, trading below the consensus price target of $102.00. Upside potential is supported by earnings beats and strategic investments in energy and autonomous driving, but risks include margin pressure, rising debt levels (46.79% debt-to-asset in 2024), and competitive auto market dynamics. Institutional sentiment remains bullish despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
